Studies available for: AIDS

See a study that interests you? Contact that study's coordinator for more information on how to participate.


Study Information:
A Comparative Randomized, Double-Blind, Double-Dummy, Multicenter Study of the Efficacy and Safety of miconazole Lauriad 50mg Administered Once a Day and Mycelex Troches (clotrimazole 10mg) Administered FiveTimes a Day in the Treatment of Oropharyngeal Candidiasis in Immunocompromised Patients
Houston, TX
Bering Omega Dental Clinic
The purpose of this research study is to evaluate the effectiveness and safety of miconazole Lauriad® Bioadhesive buccal tablet (50mg) compared with clotrimazole troche (10mg) after 14 days of treatment for oropharyngeal candidiasis (thrush) in immunocompromised patients (people with weakened immune systems).
HSC-GEN-06-0387
BioAlliance Pharma
Subject Information:
ages 18 and older
******Inclusion Criteria******* *Patients with a clinical picture of oropharyngeal candidiasis (thrush) characterized by creamy white, curdlike patches on oral mucosal surfaces (areas inside the mouth not including the teeth), removable by scraping, or typical erythematous lesions (blotchy red lesions) on oral mucosal surfaces (areas inside the mouth not including the teeth). *Confirmation of diagnosis by KOH test (direct examination). *Documented HIV seropositivity prior to enrollment. HIV-positive patients with documentation of viral load and with stable antiretroviral treatment for at least 2 months and throughout the duration of the antifungal treatment (14 days).
Study Coordinator(s) Information:
Robert Marroquin
RMarroquin@beringomega.org
409-382-5711
Robert Marroquin
Robert.Marroquin@uth.tmc.edu
Principal Investigator Information:
Dr. Mark Nichols DDS



Study Information:
Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Two-Stage Study to Assess the Efficacy and Safety of Crofelemer 125 mg, 250 mg, and 500 mg Orally Twice Daily for the Treatment of HIVAssociated Diarrhea (ADVENT Trial)
Houston, TX
School of Medicine
Purpose of the study: This study is comprised of two treatment stages. The purpose of Stage 1 is to determine the optimal dose of crofelemer for treatment of HIV-associated diarrhea. The appropriate dosage of crofelemer will be selected at an interim analysis based upon the efficacy and safety profiles of three crofelemer doses (125 mg p.o. b.i.d., 250 mg p.o. b.i.d. and 500 mg p.o. b.i.d.) compared to placebo p.o. b.i.d during the placebo-controlled treatment phase. The purpose of Stage II is to determine the proportion of HIV-positive subjects experiencing relief of diarrhea with crofelemer compared to placebo during the placebo-controlled treatment phase. Procedures: The study will be done in two stages. Both stages consist of a 10-day, single-blind, placebo screening phase; followed by randomization and a 31-day, double-blind, placebo-controlled treatment phase; and conclude with a 5-month placebo-free extension phase. In Stage I (dose-selection stage), the double-blind phase
website
HSC-MS-07-0193
Napo Pharmaceuticals
Subject Information:
more than18 year-old
Inclusion Criteria 1 >18year-old and HIV-1 positive 2 On stable ARV and associated conditions >4weeks. Stable untreated or off ARV. 3 History of persistent Diarrhea >1month. 4 Negative Pregnancy test and agreement to use acceptable contraception. 5 Clean colonoscopy within past 5 years if >50year-old. 6 Willingness to withdraw all antidiarrheal meds for the first 6 weeks of study. 7 Willingness to avoid all prohibited meds (GI targeted and opiates) for the first 6 weeks of study. 8 Willingness to comply with study: regular visits and daily IVRS entry. 9 During screening patient must report watery BM at least 5 of 7 days and urgency at least once. Exclusion Criteria 1 Pregnant or breast-feeding 2 History of immediate need for GI
Study Coordinator(s) Information:
Maria L. Martinez
Maria.L.Martinez@uth.tmc.edu
713-500-6718
Principal Investigator Information:
Roberto C. Arduino
Information on the Principal Investigator